CD22 and congenital rubella syndrome: In pediatric and young adult patients with relapsed/refractory CD22 malignancies, CAR-T cell therapies targeting CD22 as an alternative to anti-CD19 resulted in CRS in 86.2% of patients, and transient mild neurotoxic symptoms in majority of patients (ClinicalTrials.gov number: NCT02315612) (SHAH et al., 2020).